Oslo, Norway, 16 August 2012 - Algeta ASA, a company focused on the development of novel targeted cancer therapeutics, announces its results for the first half and second quarter 2012.
55989
Algeta results for the first half and second quarter 2012
51001
Finnish researchers discover mechanisms inhibiting spread of cancer cells
85026
Breast cancer drug not living up to expectations
80653
Chemicals shield may fight cancer
101808
New advance in ability to target and destroy certain cancer cells
26984
Pegasystems to announce financial results for second quarter of 2009
49489
Pfizer arthritis drug meets main goals of trial
7754
GlaxoSmithKline files for European approval of diabetes drug albiglutide
104636
Arsenic used to label antibodies for the detection of tumors
175596
Compugen discovers cancer treatment target
138888
Research could improve cancer treatment
174826
Hypercholesterolemia partnering 2007-2012
37199
Bionovo (bnvi) to present positive results from phase 2 trial of Menerba
147514
Scientists establish new class of anti-diabetic compound
124569
BioAlliance Pharma announces the
18956
Drug to strengthen bones may fight breast cancer
43638
The 2012 Ig Nobel prizes are awarded